Developmental Research Program
Developmental Research Program
批准号:
10286763
负责人:
George Ioannou
金额:
$6.52万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-06 至 2024-08-31
关键词:
Alaska NativeAmerican IndiansAreaBasic ScienceBiometryCancer Center Planning GrantCancer Research ProjectCessation of lifeCherokee IndianClinicalClinical SciencesCollaborationsColorectal CancerDevelopmentEarly DiagnosisEpidemiologyEtiologyFaceFacultyFeedbackFoundationsFred Hutchinson Cancer Research CenterFunctional disorderFundingGoalsGovernmentGrantHealth ServicesIncidenceInfrastructureInstitutionInvestmentsMalignant NeoplasmsMalignant neoplasm of liverMalignant neoplasm of lungMalignant neoplasm of prostateManuscriptsMedical centerMonitorMorbidity - disease rateNative-BornOutcomePatientsPersonsPhasePopulationPopulation StudyPreventionPrimary carcinoma of the liver cellsPrognosisProgram Research Project GrantsQuality of lifeReportingResearchResearch PersonnelResearch Project GrantsResearch ProposalsResourcesScientistSiteSourceStructureTalentsTexasTherapeuticTimeTranslational ResearchTravelUniversitiesWashingtonWomanWorkanticancer researchbasecancer health disparitycancer therapydesigndisparity eliminationethnic diversityexperiencefeasibility testinggender diversityimprovedinnovationinterestmalignant breast neoplasmmedical schoolsmeetingsmembermenmortalitymultidisciplinarynovelprogramsracial and ethnicresearch studysurvivorshiptranslational approachtribal health
中文摘要
摘要:医药和研究的核心
美国印第安人/阿拉斯加原住民(AI/AN)肝癌的发展研究计划(DRP)
差异(Li-CAD)P20计划将支持有潜力开辟新领域的早期项目。
转化肝癌研究,并最终有助于降低发病率和死亡率,
肝细胞癌(HCC)患者的生活质量。由“减贫策略”资助的项目,
迅速提出一个新的想法或概念,有可能对我们对肝脏的理解产生重大影响。
在AI/AN患者中消除差异并改善HCC的监测、早期发现和治疗
从而降低或消除HCC相关死亡率。DRP的基础设施将建立机制,
快速响应Li-CAD P20计划机构内的转化研究机会,
支持提出假设或确认可行性,以证明更大的资源投资是合理的。
发展项目将包括基础科学、临床科学和基于人口的研究,
并将在Li-CAD研究中心与其他具有肝脏P20计划和SPORE的机构之间建立合作关系
癌症和差异研究。
发展项目可能涵盖广泛的肝癌研究和治疗领域,包括
基础科学,病因学和预防(初级和二级),早期发现,预后,治疗学,
生存。总体而言,DRP旨在加强Li-CAD研究中心之间的合作,并启动
与其他具有肝癌P20项目和SPORE的机构进行互动。DRP提案将
支持基于他们的潜力成熟的原始想法或概念转化为研究项目,
将成功获得独立的资金,无论是在随后的P50或从其他政府或
基金会来源。此外,DRP旨在吸引具有不同科学知识的高级研究人员,
专业知识和初级研究人员新的转化肝癌研究。
发展研究计划的具体目标是:
1.促进创新,有影响力的早期研究的发展,包括
与Li-CAD机构的基础、临床和人口科学家进行多学科互动;
2.提供资金(1-2年)和基础设施(例如,生物样本,生物统计支持)进行快速检测
在HCC研究的所有领域中,最初的研究者发起的项目的可行性;
3.优先提供资金,以迅速利用新的机会或支持具有战略重要性的具体领域,
推进Li-CAD P20计划的转化研究目标;
4.监控(并促进)每个DRP项目的进展,并考虑将其推进到完整的P50
SPORE项目。
英文摘要
ABSTRACT: DEVELOPMENTAL AND RESEARCH PROGRAM CORE
The Developmental Research Program (DRP) of the Liver Cancer in American Indians/Alaska Natives (AI/AN)
Disparities (Li-CAD) P20 Program will support early-phase projects that have the potential to open new areas of
translational liver cancer research and ultimately, contribute to reducing morbidity and mortality and improving
quality-of-life for patients with hepatocellular carcinoma (HCC). Projects funded under the DRP are intended to
rapidly advance a new idea or concept that has the potential to substantially impact our understanding of liver
cancer to eliminate disparities and improve surveillance, early detection, and treatment of HCC in AI/AN persons
and thereby reduce or eliminate HCC-related mortality. The infrastructure of the DRP will establish mechanisms
to quickly respond to translational research opportunities within the Li-CAD P20 Program institutions that require
support to advance hypotheses or confirm feasibility in order to justify larger resource investments.
Developmental projects will include research in basic science, clinical science, and population-based studies,
and will build collaborations between Li-CAD sites and other institutions with P20 Programs and SPOREs in liver
cancer and disparities research.
Developmental projects may encompass a wide range of liver cancer research and treatment areas, including
basic science, etiology and prevention (primary and secondary), early detection, prognosis, therapeutics, and
survivorship. Collectively, the DRP is structured to strengthen collaborations between Li-CAD sites and initiate
interactions with other institutions with P20 Programs and SPOREs in liver cancer. DRP proposals will be
supported based on their potential to mature an original idea or concept into a translational research project that
will successfully attain independent funding, either within a subsequent P50 or from other government or
foundation sources. In addition, the DRP is designed to attract senior investigators with diverse scientific
expertise and junior investigators new to translational liver cancer research.
The Specific Aims for the Developmental Research Program are to:
1. Stimulate the development of innovative, impactful, early-phase research studies that include
multidisciplinary interactions with basic, clinical, and population scientists across the Li-CAD institutions;
2. Provide funding (1-2 years) and infrastructure (e.g., biospecimens, biostatistical support) to rapidly test
the feasibility of original investigator-initiated projects in all areas of HCC research;
3. Prioritize funding to rapidly exploit new opportunities or support specific areas of strategic importance for
advancing the translational research goals of the Li-CAD P20 Program; and
4. Monitor (and facilitate) the progress of each DRP project and consider their advancement to a full P50
SPORE project.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative Core
-
批准号:10286758
-
项目类别:
-
资助金额:$22.21万
-
财政年份:2021
-
负责人:George Ioannou
-
依托单位:
Developmental Research Program
-
批准号:10706329
-
项目类别:
-
资助金额:$6.39万
-
财政年份:2021
-
负责人:George Ioannou
-
依托单位:
Administrative Core
-
批准号:10706311
-
项目类别:
-
资助金额:$19.08万
-
财政年份:2021
-
负责人:George Ioannou
-
依托单位:
Risk stratification strategies and abbreviated MRI-based surveillance for early detection of HCC in high-risk AI/AN patients
-
批准号:10706318
-
项目类别:
-
资助金额:$20.07万
-
财政年份:2021
-
负责人:George Ioannou
-
依托单位:
Risk stratification strategies and abbreviated MRI-based surveillance for early detection of HCC in high-risk AI/AN patients
-
批准号:10286760
-
项目类别:
-
资助金额:$26.26万
-
财政年份:2021
-
负责人:George Ioannou
-
依托单位:
Risk stratification strategies and abbreviated MRI-based surveillance for early detection of HCC in high-risk AI/AN patients
-
批准号:10482369
-
项目类别:
-
资助金额:$20.28万
-
财政年份:2021
-
负责人:George Ioannou
-
依托单位:
Developmental Research Program
-
批准号:10482377
-
项目类别:
-
资助金额:$6.39万
-
财政年份:2021
-
负责人:George Ioannou
-
依托单位:
Administrative Core
-
批准号:10482366
-
项目类别:
-
资助金额:$19.67万
-
财政年份:2021
-
负责人:George Ioannou
-
依托单位:
Development and Validation of a Cirrhosis-specific Surgical Risk Calculator (C-SuRC)
-
批准号:10237196
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:George Ioannou
-
依托单位:
Development and Validation of a Cirrhosis-specific Surgical Risk Calculator (C-SuRC)
-
批准号:10652247
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:George Ioannou
-
依托单位:
Development and Validation of a Cirrhosis-specific Surgical Risk Calculator (C-SuRC)
-
批准号:10878798
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:George Ioannou
-
依托单位:
Cholesterol lights the fire of NASH
-
批准号:9138870
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:George Ioannou
-
依托单位:
Cholesterol lights the fire of NASH
-
批准号:9898268
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:George Ioannou
-
依托单位:
Cholesterol lights the fire of NASH
-
批准号:10394782
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:George Ioannou
-
依托单位:
Does screening for HCC reduce HCC-related mortality in HBV-infected Veterans?
-
批准号:9123351
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:George Ioannou
-
依托单位:
Does screening for HCC reduce HCC-related mortality in HBV-infected Veterans?
-
批准号:8922170
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:George Ioannou
-
依托单位:
Does screening for HCC reduce HCC-related mortality in HBV-infected Veterans?
-
批准号:10087473
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:George Ioannou
-
依托单位:
Does Screening for HCC in Cirrhotic Patients Reduce HCC-related Mortality?
-
批准号:8939210
-
项目类别:
-
资助金额:$22.93万
-
财政年份:2015
-
负责人:George Ioannou
-
依托单位:
Is HIV-associated lipodystrophy a risk factor for cirrhosis of the liver?
-
批准号:8196311
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:George Ioannou
-
依托单位:
Is HIV-associated lipodystrophy a risk factor for cirrhosis of the liver?
-
批准号:8392961
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:George Ioannou
-
依托单位:
海外基金